ClinicalTrials.gg
CompletedNCT03372486Updated May 2, 2018

Effect of Ultra-low Dose Naloxone During Supraclavicular Brachial Plexus Block on Post-operative Opioi

An interventional study of Bupivacaine plus naloxone and Bupivacaine in Upper Extremity Trauma, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-05-02.

Sponsored by Mansoura University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

Effective post-operative pain control can reduce patient morbidity and affect the patient outcome. Brachial plexus block is one of them, a popular and widely employed regional nerve block technique for perioperative anesthesia and analgesia for surgery of the upper extremity.

Different drugs have been used as adjuvants with local anesthetics in brachial plexus block to achieve quick, dense and prolonged block like Morphine, Pethidine, Clonidine, Dexmedetomidine.

Naloxone is opioid antagonists which could selectively block the excitatory effects of opioids. it release endorphins and also displace endorphins from receptor site .it also reduce the opioid induced side effects, such as vomiting, nausea, pruritus, and respiratory depression.

Read the detailed description

The aim of this study is to evaluate the effect of ultra-low dose of naloxone when added to bupivacaine %.05 in supraclavicular brachial plexus block in orthopedic upper limb surgery and if it enhances the anti-nociceptive effect of post-operative opioid

Effect of naloxone on anti-nociceptive criteria of post -operative opioid will be estimated by detecting the interval between each analgesic dose of post-operative opioid.

02

Conditions studied

  • Upper Extremity Trauma
03

In context

Lead sponsor

Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • American Society of Anesthesiology (ASA) physical state class Ι and II
  • Elective upper limb orthopedic surgery (hand, forearm and elbow)
  • Duration of surgery ≤180 min
  • ≤30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History of allergy to the drug of the study.
  • Coagulation disorders
  • Infection at the puncture site.
  • Pregnancy
  • Opioid abuse.
  • Abuse of tranquilizers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Bupivacaine plus naloxone

    Patients will receive brachial plexus block using bupivacaine plus naloxone.

    Drug: Bupivacaine plus naloxone

  • Placebo comparator
    Bupivacaine

    Patients will receive brachial plexus block using bupivacaine.

    Drug: Bupivacaine

Interventions

  • DrugBupivacaine plus naloxone

    Drug pages: Bupivacaine · Naloxone

    Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)

  • DrugBupivacaine

    Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline

06

What researchers measure

Primary outcomes

  1. Effect of ultra-low dose naloxone on the post operative opioid

    by estimate the analgesic requirements of opioids and the interval between each opioid dose in 48 hour post operative

    Time frame: for 48 hours after surgery

Secondary outcomes

  1. Duration of sensory block

    will be defined as the time interval between the complete sensory block (complete absence of pinprick response) and first experience with postoperative pain

    Time frame: For 48 hours after surgery

  2. Duration of motor block

    defined as the time interval between complete paralysis (Lovett rating scale = 0) and complete recovery (Lovett rating scale = 6)

    Time frame: For 48 hours after surgery

  3. Onset time of sensory block

    defined as the time between the end of the last injection and complete absence of pinprick response in all nerve distribution

    Time frame: For 48 hours after surgery

  4. Onset time of motor block

    defined as the time between the end of the last injection and complete paralysis (Lovett rating scale = 0) in all nerve distributions

    Time frame: For 48 hours after surgery

  5. Severity of post-operative pain

    will be measured by visual analogue scale (VAS) where 0 was equal to no pain and 10 indicated the worst possible pain

    Time frame: For 48 hours after surgery

  6. 1st time of analgesic request

    First need for rescue opioid after surgery

    Time frame: For 48 hours after surgery

07

Study locations

1 site
  • Mansoura University, Central Hospital, emergency Unit
    Mansourah, Dakahlia 050, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03372486
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Dec 18, 2017
Primary completion
Apr 10, 2018
Completion
Apr 25, 2018
Last update
May 2, 2018

Study contacts

Doaa G Diab, MD
principal investigator · Assistant Professor of Anesthesia and Surgical Intensive Care

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Naloxone

Start the discussion